[A12-16] Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 15.02.2013
Project no.:
A12-16
Commission:
Commission awarded on 15.12.2012 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-33 | Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-14 | Addendum to Commission A12-16 Saxagliptin/metformin | Commission completed |
| A16-43 | Saxagliptin/metformin - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-12 | Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2013-05-02 A G-BA decision was published.